BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23065688)

  • 1. Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma.
    Rednam S; Scheurer ME; Adesina A; Lau CC; Okcu MF
    Pediatr Blood Cancer; 2013 Apr; 60(4):593-8. PubMed ID: 23065688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton radiation therapy for pediatric medulloblastoma and supratentorial primitive neuroectodermal tumors: outcomes for very young children treated with upfront chemotherapy.
    Jimenez RB; Sethi R; Depauw N; Pulsifer MB; Adams J; McBride SM; Ebb D; Fullerton BC; Tarbell NJ; Yock TI; Macdonald SM
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):120-6. PubMed ID: 23790826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current and future strategies in interdisciplinary treatment of medulloblastomas, supratentorial PNET (primitive neuroectodermal tumors) and intracranial germ cell tumors in childhood].
    Kortmann RD; Kühl J; Timmermann B; Calaminus G; Dieckmann K; Wurm R; Sörensen N; Urban C; Göbel U; Bamberg M
    Strahlenther Onkol; 2001 Sep; 177(9):447-61. PubMed ID: 11591018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.
    Brown AL; Lupo PJ; Okcu MF; Lau CC; Rednam S; Scheurer ME
    Cancer Med; 2015 Nov; 4(11):1679-86. PubMed ID: 26400460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumors.
    Allen JC; Donahue B; DaRosso R; Nirenberg A
    Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1155-61. PubMed ID: 8985038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolongation of radiotherapy duration is associated with inferior overall survival in patients with pediatric medulloblastoma and central nervous system primitive neuroectodermal tumors.
    Baliga S; Bajaj BVM; Kabarriti R; Grassberger C; Patteson B; Yeap B; Fox JL; Garg MK; Yock TI
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28558. PubMed ID: 32710698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study.
    Yock TI; Yeap BY; Ebb DH; Weyman E; Eaton BR; Sherry NA; Jones RM; MacDonald SM; Pulsifer MB; Lavally B; Abrams AN; Huang MS; Marcus KJ; Tarbell NJ
    Lancet Oncol; 2016 Mar; 17(3):287-298. PubMed ID: 26830377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
    Allen J; Donahue B; Mehta M; Miller DC; Rorke LB; Jakacki R; Robertson P; Sposto R; Holmes E; Vezina G; Muraszko K; Puccetti D; Prados M; Chan KW
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1006-11. PubMed ID: 19356859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review.
    Vieira WA; Weltman E; Chen MJ; da Silva NS; Cappellano AM; Pereira LD; Gonçalves MI; Ferrigno R; Hanriot RM; Nadalin W; Odone Filho V; Petrilli AS
    Radiat Oncol; 2014 Jul; 9():158. PubMed ID: 25041714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.
    Barahmani N; Carpentieri S; Li XN; Wang T; Cao Y; Howe L; Kilburn L; Chintagumpala M; Lau C; Okcu MF
    Neuro Oncol; 2009 Jun; 11(3):292-300. PubMed ID: 18952980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients.
    Olgun Y; Aktaş S; Altun Z; Kırkım G; Kızmazoğlu DÇ; Erçetin AP; Demir B; İnce D; Mutafoğlu K; Demirağ B; Ellidokuz H; Olgun N; Güneri EA
    Int J Pediatr Otorhinolaryngol; 2016 Nov; 90():64-69. PubMed ID: 27729156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
    Fouladi M; Chintagumpala M; Ashley D; Kellie S; Gururangan S; Hassall T; Gronewold L; Stewart CF; Wallace D; Broniscer A; Hale GA; Kasow KA; Merchant TE; Morris B; Krasin M; Kun LE; Boyett JM; Gajjar A
    J Clin Oncol; 2008 Aug; 26(22):3749-55. PubMed ID: 18669462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antioxidant enzyme polymorphisms and neuropsychological outcomes in medulloblastoma survivors: a report from the Childhood Cancer Survivor Study.
    Brackett J; Krull KR; Scheurer ME; Liu W; Srivastava DK; Stovall M; Merchant TE; Packer RJ; Robison LL; Okcu MF
    Neuro Oncol; 2012 Aug; 14(8):1018-25. PubMed ID: 22661588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy.
    Prados MD; Wara W; Edwards MS; Ater J; Rabbit J; Lamborn K; Davis R; Levin VA
    Pediatr Neurosurg; 1996 Oct; 25(4):174-81. PubMed ID: 9293544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor.
    Sung KW; Yoo KH; Cho EJ; Koo HH; Lim DH; Shin HJ; Ahn SD; Ra YS; Choi ES; Ghim TT
    Pediatr Blood Cancer; 2007 Apr; 48(4):408-15. PubMed ID: 17066462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosurgery or hypofractionated stereotactic radiotherapy after craniospinal irradiation in children and adults with medulloblastoma and ependymoma.
    Napieralska A; Brąclik I; Radwan M; Mandera M; Blamek S
    Childs Nerv Syst; 2019 Feb; 35(2):267-275. PubMed ID: 30515559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there an increased risk of spinal relapse in standard-risk medulloblastoma/primitive neuroectodermal tumor patients who receive only a reduced dose of craniospinal radiotherapy?
    Burcu A; Nazan Ç; Özgür Ö; Serra K; Mehmet K; Serap A; Bengü D; Canan V; Haldun Ö; Savaş K; Tuncer T; Taner A; Yeşim E; Ömer K; Yavuz A
    Childs Nerv Syst; 2018 Sep; 34(9):1657-1662. PubMed ID: 29868932
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Kautiainen RJ; Dwivedi B; MacDonald TJ; King TZ
    Child Neuropsychol; 2020 Aug; 26(6):739-753. PubMed ID: 32054423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutathione S-Transferase Pi 1 (GSTP1) Gene 313 A/G (rs1695) polymorphism is associated with the risk of urinary bladder cancer: Evidence from a systematic review and meta-analysis based on 34 case-control studies.
    Song Y; Chen J; Liu K; Zhou K; Lu Y; Wang X; Yang Y; Liu X
    Gene; 2019 Nov; 719():144077. PubMed ID: 31454540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.